[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100356441":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":20,"studyPopulation":21,"armGroups":22,"interventions":29,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":70,"collaborators":72,"id":76,"slug":16,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":16,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":16,"enrollmentInfo":84,"targetDuration":16,"studyType":87,"phases":16,"briefSummary":88,"conditions":89,"keywords":16,"overallStatus":52,"whyStopped":16,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Southern California","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Time to diagnosis of acute graft versus (vs.) host disease (aGVHD)","Will be calculated as the time from stem cell infusion until the date of the diagnosis of aGVHD. If a patient dies prior to day 100 and does not have aGVHD, the patient will be censored at the time of death; all patients without aGVHD will be censored on day 100.","Up to 4 years",{"measure":14,"description":15,"timeFrame":12},"Time to diagnosis of relapse","Will be calculated as the time from stem cell infusion until the date of the of the diagnosis of relapse Patients who die of treatment toxicity or other cause, prior to relapse, will be censored at the time of death; all patients will be censored at 365 days following transplant.",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":19,"maskingInfo":16},"CASE_ONLY","PROSPECTIVE","PRIMARY OBJECTIVES:\n\nI. Characterize the T cell receptor (TCR) repertoire in acute myeloid leukemia (AML) patients before and after receiving hematologic stem cell transplantation (HSCT).\n\nII. Identify molecular changes (germline variants and somatic mutations) that contribute to shaping the TCR repertoire.\n\nOUTLINE:\n\nPatents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for ribonucleic acid (RNA)-based next generation sequencing of TCRA and TCRB genes.","Patients with AML scheduled to undergo HSCT",[23],{"label":24,"type":16,"description":25,"interventionNames":26},"Ancillary-correlative (next generation sequencing)","Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for RNA-based next generation sequencing of TCRA and TCRB genes.",[27,28],"Procedure: Biospecimen Collection","Other: Laboratory Biomarker Analysis",[30,35],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":16},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[24],{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":16},"Laboratory Biomarker Analysis","Correlative studies",[24],[40],{"name":41,"affiliation":5,"role":42},"Houda Alachkar, PharmD, PhD","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":16,"email":48},"Christine Duran","CONTACT","323-865-0371","Duran_C@med.usc.edu",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"USC \u002F Norris Comprehensive Cancer Center","RECRUITING","Los Angeles","California","90033","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-118.24368,34.05223,{"lat":62,"lon":61},[65,69],{"name":66,"role":46,"phone":67,"phoneExt":16,"email":68},"Houda Alachkar","323-442-2696","alachkar@usc.edu",{"name":66,"role":42,"phone":16,"phoneExt":16,"email":16},{"type":71,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[73],{"name":74,"class":75},"National Cancer Institute (NCI)","NIH","100356441",false,"NCT03921047","Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant","Characterization of T-cell Repertoire in Patients With AML Undergoing HSCT Through Next-Generation Sequencing of T Cell Receptor Alpha (TCRA) and T Cell Receptor Beta (TCRB) Genes","Inclusion Criteria:\n\n* Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC)\n\nExclusion Criteria:\n\n* Inability to provide consent because of severe mental disorders\n* Donor unwilling to provide consent","ALL","18 Years",{"count":85,"type":86},250,"ESTIMATED","OBSERVATIONAL","This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant. Characterizing T-cell repertoire may help to understand if immune system plays a significant role in high risk patients with acute myeloid leukemia.",[90],"Acute Myeloid Leukemia","2026-05-29",{"date":93,"type":94},"2026-06-03","ACTUAL",{"date":96,"type":94},"2018-04-12",{"date":98,"type":86},"2027-12-31",{"name":5,"class":6},1]